Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

dirkfrank Jan. 27 at 9:38 PM

$PRQR read on X seems more like a perpetual research company b/c actual clinical data seems rather sparce to nonexistent and constantly delaying data. I have a very small amount of stock just so I don't forget about them.

1 · Reply

Kyle7776 Jan. 27 at 7:09 AM

$PRQR the only catalyst for this is target engagement data. What upside can we expect?

1 · Reply

RandomInvestor777 Jan. 26 at 11:08 PM

$PRQR Got an answer from IR. apparently they contact DMC after the 4 weeks then start doing. they don't wait 12 weeks after (that's the followup). So Data may be well in line with H1 but likely May-June.

2 · Reply

RandomInvestor777 Jan. 24 at 12:05 AM

$PRQR since the cohorts have a 4 week dosing and 12 weeks follow up. then IDMC meeting for safety before dose esclation. this means second cohort and third cohort should take at least 6 months assuming IDMC meets same day. Assuming first cohort is already finished. How is this meeting the 1H2026 deadline?

1 · Reply

DocPharm Jan. 23 at 10:33 PM

$PRQR .

1 · Reply

ACH50 Jan. 22 at 6:26 PM

$PRQR @LeftyT Approximately Lilly 16.4% Privium 15.5% (conglomerated) Van Herk 13.6% That’s 45.5% owned by just these three entities. Add in Adage’s 6% and over 51% of $PRQR owned by these 4 entities. That is interesting.

2 · Reply

johnnygogogo Jan. 22 at 5:32 PM

$PRQR

0 · Reply

LeftyT Jan. 22 at 4:30 PM

$PRQR The 13G from Privium now totals 15% of the company. Are they capped at this level, or can they add more with one of their affiliates? Inquiring minds want to know! https://archive.fast-edgar.com/20260120/AUB2922C822272ZK222U2CZZW4R372T2Z282/

2 · Reply

gsc1980 Jan. 21 at 9:51 PM

$PRQR this thing is so underestimated.

2 · Reply

johnnygogogo Jan. 21 at 4:51 PM

$PRQR

0 · Reply

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Dec 1, 2025, 8:00 AM EST - 2 months ago

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 2 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 6:46 PM EST - 3 months ago

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Oct 20, 2025, 8:00 AM EDT - 3 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 13, 2025, 8:30 AM EDT - 3 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 7:00 AM EDT - 6 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 6 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 7 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 9 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 7:00 AM EDT - 9 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 2, 2025, 8:00 AM EDT - 9 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 9 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 10 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 7:00 AM EDT - 11 months ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 9, 2023, 8:00 AM EDT - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 7, 2023, 8:00 AM EST - 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 9, 2022, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

dirkfrank Jan. 27 at 9:38 PM

1 · Reply

Kyle7776 Jan. 27 at 7:09 AM

$PRQR the only catalyst for this is target engagement data. What upside can we expect?

1 · Reply

RandomInvestor777 Jan. 26 at 11:08 PM

2 · Reply

RandomInvestor777 Jan. 24 at 12:05 AM

1 · Reply

DocPharm Jan. 23 at 10:33 PM

$PRQR .

1 · Reply

ACH50 Jan. 22 at 6:26 PM

2 · Reply

johnnygogogo Jan. 22 at 5:32 PM

$PRQR

0 · Reply

LeftyT Jan. 22 at 4:30 PM

2 · Reply

gsc1980 Jan. 21 at 9:51 PM

$PRQR this thing is so underestimated.

2 · Reply

johnnygogogo Jan. 21 at 4:51 PM

$PRQR

0 · Reply

justfacts1 Jan. 21 at 4:44 PM

$PRQR down we go.

0 · Reply

justfacts1 Jan. 21 at 3:05 PM

$PRQR Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis. Hopefully we can have similar news)

0 · Reply

Market_Max Jan. 20 at 4:29 PM

$PRQR someone said the key product PRQR has is it's partnership with $LLY. That deal is worth $3.75 Billion if all milestones are met. And I agree, thats the only reason to be in this right now. The indications PRQR is pursuing outside of the Lilly deal is way too early to attract any significant value. The only value that can deduced from those other indications is SAFETY of the new Modality that ADAR represents - that is for outsiders like us who are not privy to whatever the indications/stage of progress inherent in the Lilly deal. So, know your risk and expectations accordingly!

4 · Reply

dirkfrank Jan. 16 at 8:19 AM

$PRQR who is leaving the building?

3 · Reply

justfacts1 Jan. 15 at 11:34 PM

$PRQR our strategic collaboration with Lilly, which achieved $4.5 million in milestones in 2025, these advances underscore the strength and versatility of our Axiomer platform. As we enter 2026, we remain focused on executing on our priorities and advancing innovative RNA editing therapies on our Axiomer platform to address high unmet-need patient populations and create long-term value for both patients and shareholders.” Long term value!)

2 · Reply

ehpats Jan. 15 at 10:45 PM

$PRQR We are being kept in the dark with regards to the deal with lly. 10 targets with milestone payments attached. 4.5m achieved in 2025, peanuts. It would be nice to know what’s on the table for 2026. Prqr has to be ready to move to human trials for some targets. How much are the attached milestones? Be nice to know if we have the potential to add another $4.5m or 45m or who knows 🤷 What a f’ing gamble this is. 🤦

2 · Reply

FutureInvesting777 Jan. 15 at 9:19 PM

$PRQR when sepofarsen “failed,” this plummeted from around 6 dollars a share to around 60 cents a share. Let’s hope this is not the case this time.

1 · Reply

anlkrts Jan. 15 at 8:46 PM

$PRQR stupid assholes! We are going lower and lower every fucking single day!

0 · Reply

ehpats Jan. 15 at 4:53 PM

$PRQR from a few weeks back but still an excellent take https://beyondspx.com/quote/PRQR/analysis/proqr-s-rna-editing-gamble-first-human-data-will-make-or-break-the-axiomer-platform

1 · Reply

dirkfrank Jan. 13 at 10:02 PM

$PRQR i need a friend to gogogo

1 · Reply

justfacts1 Jan. 13 at 3:30 PM

$PRQR on this rate , will will reach 1 before H1 ends!

2 · Reply

Geert07 Jan. 12 at 8:17 PM

$PRQR Updated Corporate presentation is now available: https://www.proqr.com/investors-media/proqr-corporate-presentation The data they plan to publish in H1 are key, these will show if their RNA editing technology works in humans, thus validating the Axiomer platform. If data are good, it should give the share price a big boost. I’m optimistic, primate data were good. And safety also doesn’t appear to be an issue, given the results that were published last week.

0 · Reply

Market Cap	177.81M
Revenue (ttm)	20.46M
Net Income (ttm)	-30.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-146.82%
Debt to Equity Ratio	0.08

Volume	519,800
Avg Vol	535,772
Day's Range	N/A - N/A
Shares Out	105.21M
Stochastic %K	47%
Beta	0.19
Analysts	Strong Sell
Price Target	$8.88